A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)
Recruiting now · Phase 2/Phase 3 · Has a placebo group
Conditions studied: Metastatic Colorectal Cancer
In brief
This is a two-arm, randomized, double-blinded, multicenter phase III clinical study to evaluate the clinical efficacy of Serplulimab (HLX10) in Combination With Bevacizumab and Chemotherapy (XELOX) Versus Placebo in Combination With Bevacizumab and Chemotherapy (XELOX) in First-line Treatment of Patients With Metastatic Colorectal Cancer (mCRC)
Key facts
- Study ID
- NCT04547166
- Run by
- Shanghai Henlius Biotech
- People needed
- 568
- Starts
- 2021-03-10
- Expected to finish
- 2026-12-30
- Last updated by the study team
- 2024-10-17
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Center for Cancer Prevention and Treatment of Sun Yat-sen University — Guangzhou, Guangdong, China (enrolling)
- Zhejiang Cancer Hospital — Hangzhou, Zhejiang, China (enrolling)
- Linyi Cancer Hospital — Linyi, China (enrolling)
- Fudan University Affiliated Oncology Hospital — Shanghai, China (enrolling)
- National Cancer Center — Kashiwa, Japan
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.